Cartesian Therapeutics (RNAC) Interest & Investment Income (2015 - 2026)

Cartesian Therapeutics (RNAC) has 11 years of Interest & Investment Income data on file, last reported at $1.0 million in Q1 2026.

• On a quarterly basis, Interest & Investment Income fell 49.08% year-over-year to $1.0 million in Q1 2026; TTM through Mar 2026 was $5.6 million, a 32.14% decrease from a year earlier, with the FY2025 full-year figure at $6.6 million, down 10.93% from the prior year.
• Interest & Investment Income for Q1 2026 stood at $1.0 million, down from $1.3 million in the prior quarter.
• Over the last five years, Interest & Investment Income for RNAC reached as high as $5.0 million in Q4 2023 and fell as low as $11000.0 in Q1 2023.
• Historically, Interest & Investment Income has averaged $1.4 million across 5 years, with a median of $1.2 million in 2024.
• Across the five-year window, Interest & Investment Income surged 25968.42% in 2023 and plunged 50.45% in 2024, its largest moves.
• Year by year, Interest & Investment Income stood at $19000.0 in 2022, then jumped by 25968.42% to $5.0 million in 2023, then plunged by 50.45% to $2.5 million in 2024, then plunged by 48.33% to $1.3 million in 2025, then declined by 19.09% to $1.0 million in 2026.
• Per Business Quant data, the three most recent Interest & Investment Income figures were $1.0 million in Q1 2026, $1.3 million in Q4 2025, and $1.5 million in Q3 2025.